An Open-label,Randomized,Controlled Study to Evaluate the Safety and Efficacy for Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 06 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 07 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016.